PURE BIOLOGICS ZY -10
Research PURE BIOLOGICS ZY -10 (PQB) on Bullrun: market cap EUR 7.85M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPQB
- ExchangeF
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 7.85M
- Financial periodQ1 2026
- RevenuePLN 0
- Net income-PLN 2.24M
- Free cash flow-PLN 3.17M
Valuation Snapshot
latest market cap is EUR 7.85M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 7.85M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About PURE BIOLOGICS ZY -10
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PURE BIOLOGICS ZY -10's market cap?
PURE BIOLOGICS ZY -10's market capitalization is EUR 7.85M.
What does PURE BIOLOGICS ZY -10 do?
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.